Encainide hydrochloride
Names
[ CAS No. ]:
66794-74-9
[ Name ]:
Encainide hydrochloride
[Synonym ]:
(+-)-2'-(2-(1-Methyl-2-piperidyl)ethyl)-p-anisanilide monohydrochloride
4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide,hydrochloride
Benzamide,4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-,monohydrochloride,(+-)
Encainide hydrochloride
4-Methoxy-2'-(2-(1-methyl-2-piperidyl)ethyl)benzanilide hydrochloride
Encainide HCl
Encainide hydrochloride (USAN)
Enkaid
Biological Activity
[Description]:
[Related Catalog]:
[In Vivo]
[References]
Chemical & Physical Properties
[ Density]:
1.106g/cm3
[ Boiling Point ]:
439.9ºC at 760mmHg
[ Molecular Formula ]:
C22H29ClN2O2
[ Molecular Weight ]:
388.93100
[ Flash Point ]:
219.8ºC
[ Exact Mass ]:
388.19200
[ PSA ]:
41.57000
[ LogP ]:
5.17730
[ Storage condition ]:
2-8°C
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- CV5521500
- CHEMICAL NAME :
- Benzamide, 4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)pheny l)-, monohydrochloride, (+-)-
- CAS REGISTRY NUMBER :
- 66794-74-9
- LAST UPDATED :
- 199604
- DATA ITEMS CITED :
- 7
- MOLECULAR FORMULA :
- C22-H28-N2-O2.Cl-H
- MOLECULAR WEIGHT :
- 388.98
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 57 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 86 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 16 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 43 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 17 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Primate - monkey
- DOSE/DURATION :
- 8 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 5500 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
Safety Information
[ Symbol ]:
GHS06
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301-H315-H319-H335
[ Precautionary Statements ]:
P261-P301 + P310-P305 + P351 + P338
[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
[ Hazard Codes ]:
T
[ Risk Phrases ]:
25-36/37/38
[ Safety Phrases ]:
26-45
[ RIDADR ]:
UN 2811 6.1/PG 3
[ RTECS ]:
CV5521500
Articles
Clin. Pharm. 6(11) , 839-50, (1987)
The chemistry, electrophysiology, pharmacokinetics, clinical use and efficacy, adverse effects, drug interactions, and dosage of encainide hydrochloride and flecainide acetate are reviewed. Encainide ...
ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia.J. Cardiovasc. Electrophysiol. 9(11) , 1167-72, (1998)
Three patients in whom Class IC sodium channel blockers induced ST segment elevation in leads V1 through V3 are described. The underlying electrophysiologic mechanism, implications for drug-induced pr...
Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST).Ann. Epidemiol. 6(2) , 93-101, (1996)
Patient adherence to therapy is essential to assess treatment efficacy, particularly in clinical trials. Active treatment usually is expected to benefit patients. The healthy adherer effect, the assoc...